Login / Signup

Time-to-first-event versus recurrent-event analysis: points to consider for selecting a meaningful analysis strategy in clinical trials with composite endpoints.

Geraldine RauchMeinhard KieserHarald BinderAntoni Bayes-GenisAntje Jahn-Eimermacher
Published in: Clinical research in cardiology : official journal of the German Cardiac Society (2018)
When planning trials with a composite endpoint, researchers, and regulatory agencies should be aware that the model choice affects the estimated treatment effect and its interpretation.
Keyphrases
  • clinical trial
  • transcription factor
  • randomized controlled trial
  • double blind